Maurice Mezzino - Arena Pharmaceuticals Senior Vice President - Corporate Development

ARNADelisted Stock  USD 99.99  0.00  0.00%   

President

Mr. Maurice J. Mezzino is Senior Vice President Corporationrationrate Development of the company since December 2015, and previously served as our Vice President, Corporationrationrate Development from August 2011 to December 2015. Mr. Mezzino has over 30 years of experience in the biopharmaceutical industry related to partnering, assessing new businesses, products and markets, and planning with respect to strategy and operations. Mr. Mezzino has successfully led crossfunctional teams to source, structure, negotiate and execute deal transactions on products and technologies in various stages of commercialization and in multiple therapeutic markets. Mr. Mezzino served in a consulting capacity as Acting Vice President of Business Development for BeiGene, Ltd., an immunooncology company, from January 2011 to August 2011 as Vice President, Chief Business Officer at Ceregene, Inc., a former neurodegenerative diseasefocused gene therapy company, from 2008 to 2010 in various positions at IDEC Pharmaceuticals Corporationrationration, a biopharmaceutical company and continuing at Biogen Idec Inc. after the since 2015.
Age 60
Tenure 9 years
Phone858 453-7200
Webwww.arenapharm.com

Arena Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (34.53) % which means that it has lost $34.53 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (70.3) %, meaning that it created substantial loss on money invested by shareholders. Arena Pharmaceuticals' management efficiency ratios could be used to measure how well Arena Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 51.31 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Arena Pharmaceuticals has a current ratio of 8.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Arena Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Arena Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arena Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arena to invest in growth at high rates of return. When we think about Arena Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Jamie BeggsAvient Corp
47
Eric HinkefentAMCON Distributing
53
Daniel MonagleMinerals Technologies
58
Vinod PurayathAvient Corp
45
Cindi BuckwalterMinerals Technologies
N/A
Michael CipollaMinerals Technologies
66
Thomas MeekMinerals Technologies
67
Douglas MaygerMinerals Technologies
66
Patrick CarpenterMinerals Technologies
52
Courtland PearsonLifevantage
N/A
Andrew PlummerAMCON Distributing
50
Jonathan HastingsMinerals Technologies
61
Michelle ObornVirchowLifevantage
44
Matthew GarthMinerals Technologies
46
Michael JohnsonMinerals Technologies
55
Rand MendezMinerals Technologies
53
Andrew JonesMinerals Technologies
61
Brett ArgirakisMinerals Technologies
59
Rick HoneyMinerals Technologies
N/A
Charles SchmadererAMCON Distributing
55
Kenneth WolfNatural Alternatives Internatio
63
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. Arena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 448 people. Arena Pharmaceuticals (ARNA) is traded on NASDAQ Exchange in USA and employs 448 people.

Management Performance

Arena Pharmaceuticals Leadership Team

Elected by the shareholders, the Arena Pharmaceuticals' board of directors comprises two types of representatives: Arena Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arena. The board's role is to monitor Arena Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arena Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arena Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Garry Neil, Director
Randall Woods, Independent Director
Maurice Mezzino, Senior Vice President - Corporate Development
Harry Hixson, Independent Director
Phillip Schneider, Independent Director
Steven Spector, Executive Vice President General Counsel, Secretary
Preston Klassen, Executive Vice President - Research & Development, Chief Medical Officer
Jennifer Jarrett, Director
Jennifer Bielasz, Vice President - Accounting, Controller, Principal Accounting Officer
Robert Lisicki, Executive Vice President and Chief Commercial Officer
Tina Nova, Independent Director
Craig Audet, Head of Global Regulatory Affairs and Sr. VP of Operations
Jayson Dallas, Director
Kieran Gallahue, Director
Amit Munshi, President CEO, Director
William Shanahan, Senior Vice President Chief Medical Officer
Donald Belcher, Independent Director
Scott Bice, Independent Director
Dominic Behan, Executive Vice President Chief Scientific Officer, Director
Vincent Aurentz, Executive Vice President and Chief Business Officer
Manmeet Soni, Director
Kevin Lind, CFO, Executive Vice President
Christine White, Lead Independent Director
Oliver Fetzer, Director
Paul Audhya, Senior Vice President - Medical Affairs

Arena Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arena Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Arena Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arena Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arena Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Arena Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arena Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arena Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arena Pharmaceuticals to buy it.
The correlation of Arena Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arena Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arena Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arena Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Consideration for investing in Arena Stock

If you are still planning to invest in Arena Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Arena Pharmaceuticals' history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments